NASDAQ:QNRX Quoin Pharmaceuticals Q2 2026 Earnings Report $4.29 -0.09 (-2.05%) Closing price 04:00 PM EasternExtended Trading$4.39 +0.11 (+2.45%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Quoin Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.61Beat/MissN/AOne Year Ago EPSN/AQuoin Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuoin Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Quoin Pharmaceuticals Earnings HeadlinesQuoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeJuly 9, 2026 | finanznachrichten.deQuoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin SyndromeJuly 9, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.July 23 at 1:00 AM | Paradigm Press (Ad)Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeJune 30, 2026 | finanznachrichten.deQuoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton SyndromeJune 30, 2026 | globenewswire.comQuoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton SyndromeJune 23, 2026 | globenewswire.comSee More Quoin Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email. Email Address About Quoin PharmaceuticalsQuoin Pharmaceuticals (NASDAQ:QNRX), Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.View Quoin Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip BattleAlphabet Crushed Earnings, But One Number Spooked the MarketPremium Retail’s Stress Test Is Separating Winners From LosersGE Vernova Just Sent a Mixed AI Signal to InvestorsOtis Took Another Guidance Cut—But the Story Isn't OverPhilip Morris Trimmed Guidance, But Its Growth Story Looks UnshakenD-Wave Quantum or a Quantum ETF: Which Is the Better Bet? Upcoming Earnings Verizon Communications (7/24/2026)ENI (7/24/2026)Phillips 66 (7/24/2026)SLB (7/24/2026)American Express (7/24/2026)HCA Healthcare (7/24/2026)Canadian National Railway (7/24/2026)Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
